Chimeric Antigen Receptor News and Research

RSS

New nanocapsule treatment boosts immune response against solid tumors

UCLA researchers have developed a new treatment method using a tiny nanocapsule to help boost the immune response, making it easier for the immune system to fight and kill solid tumors.

11 Oct 2023

New form of cellular immunotherapy shows promise against brain tumors in mice

Scientists from the German Cancer Research Center (DKFZ) and the University Medical Center Mannheim (UMM) successfully tested a new form of cellular immunotherapy against brain tumors in mice for the first time.

26 Sep 2023

New CAR T cell therapy approach minimizes severe side effects

In recent years, cancer researchers have hailed the arrival of chimeric antigen receptor T cell (CAR T) therapy, which has delivered promising results, transforming the fight against various forms of cancer. The process involves modifying patients' T-cells to target cancer cells, resulting in remarkable success rates for previously intractable forms of cancer.

19 Sep 2023

NCCN publishes new resource on options, benefits of care approaches for pediatric Hodgkin lymphoma

The National Comprehensive Cancer Network today announced the publication of NCCN Guidelines for Patients®: Hodgkin Lymphoma in Children.

22 Aug 2023

Unveiling hidden threats: clustering loops in CAR-T cells impact cancer therapy

How complementarity-determining region (CDR) loops in the single-chain variable fragment (scFv) influence chimeric antigen receptor (CAR)-T cell behavior.

14 Aug 2023

Ovarian cancer patients enrolled in first-in-human trial of CAR T cell therapy

Recently published preclinical data by City of Hope scientists shows the immunotherapy is effective. Advanced ovarian cancer patients are now being enrolled in a Phase 1 first-in-human trial.

10 Aug 2023

Study explores the diverse expression patterns of T cell priming markers across cancers

A recent study explored transcriptomics of T-cell priming markers (TPMs) across different cancers.

10 Aug 2023

Immunotherapy after stem cell transplantation effectively combats certain childhood nerve tumors

Scientists at St. Anna Children's Cancer Research Institute and the Eberhard Karls University of Tübingen have shown that immunotherapy after stem cell transplantation effectively combats certain nerve tumors in children.

9 Aug 2023

The immune-modulatory effect of lenvatinib investigated in new study

Researchers explore the effect of lenvatinib treatment on patients with advanced thyroid cancer.

9 Aug 2023

Tails on engineered T cells could help fight cancer

In a promising form of immunotherapy known as CAR T-cell (chimeric antigen receptor) therapy, the patient's T cells are engineered to better recognize and attack antigens on the surface of cancer cells.

27 Jul 2023

Two infusions of IL-15-expressing CAR NK Cells boost survival in lymphoma mouse models

A new study led by researchers at The University of Texas MD Anderson Cancer Center discovered loss of metabolic fitness in chimeric antigen receptor (CAR) natural killer (NK) cells is a critical mechanism of resistance, with infused cells gradually losing the ability to compete with tumor cells for nutrients, leading to tumor relapse.

26 Jul 2023

Using a vaccine to boost the response of engineered T cells

Engineering T cells to destroy cancer cells has shown success in treating some types of cancer, such as leukemia and lymphoma. However, it hasn't worked as well for solid tumors.

5 Jul 2023

New project aims to improve the efficacy and safety of CAR T therapies for solid tumors

Partners in the international consortium CAR T-REX announce the awarding of a highly competitive EIC Pathfinder Open grant, following the positive evaluation of their project entitled 'CAR T Cells Rewired to Prevent EXhaustion in the Tumour Microenvironment'.

23 Jun 2023

First successful Phase 2 trial uses cutting-edge RNA CAR-T therapy to treat autoimmunity

Cartesian Therapeutics, a clinical-stage biotechnology company pioneering cell therapies for autoimmune diseases, announced today the publication of a landmark paper in The Lancet Neurology.

22 Jun 2023

New base-edited T-cells proven effective to treat lymphoblastic leukemia

Three young patients with relapsed T-cell leukemia have now been treated with base-edited T-cells, as part of a 'bench-to-bedside' collaboration between UCL and Great Ormond Street Hospital for Children (GOSH).

15 Jun 2023

Phase III ZUMA-7 trial: Patients with high-risk large B-cell lymphoma lived longer with axi-cel

Patients with early relapsed or refractory large B-cell lymphoma had significantly improved overall survival when treated with the chimeric antigen receptor (CAR) T cell therapy axicabtagene ciloleucel (axi-cel) when compared to the current standard-of-care chemoimmunotherapy, according to results of the Phase III ZUMA-7 trial reported by researchers from The University of Texas MD Anderson Cancer Center.

5 Jun 2023

Novel computational platform can expand the pool of cancer immunotherapy targets

Researchers at Children's Hospital of Philadelphia (CHOP) and the University of California, Los Angeles (UCLA) have developed a computational platform capable of discovering tumor antigens derived from alternative RNA splicing, expanding the pool of cancer immunotherapy targets.

17 May 2023

Phase 1 clinical trial of CAR-NKT cell therapy shows promising results in neuroblastoma patients

Researchers at Baylor College of Medicine/Texas Children's Cancer Center and collaborating institutions report interim results from a first-in-human phase 1 clinical trial evaluating the safety, antitumor activity and immunological characteristics of a genetically engineered natural killer T (NKT) cell immunotherapy for neuroblastoma, a childhood tumor that most commonly arises in the adrenal gland.

15 May 2023

New approach for efficient engineering of cell and gene therapies

A new approach to the genetic engineering of cells promises significant improvements in speed, efficiency, and reduction in cellular toxicity compared to current methods.

28 Apr 2023

New approach to CAR T-cell therapy shows promise against small cell lung cancer in preclinical study

A new approach to chimeric antigen receptor T-cell (CAR T) therapy has shown great promise against small cell lung cancer (SCLC) in a preclinical study.

25 Apr 2023